Elisa Zanardi

1.3k total citations
56 papers, 785 citations indexed

About

Elisa Zanardi is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Elisa Zanardi has authored 56 papers receiving a total of 785 indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Pulmonary and Respiratory Medicine, 28 papers in Oncology and 16 papers in Cancer Research. Recurrent topics in Elisa Zanardi's work include Prostate Cancer Treatment and Research (19 papers), Renal cell carcinoma treatment (8 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Elisa Zanardi is often cited by papers focused on Prostate Cancer Treatment and Research (19 papers), Renal cell carcinoma treatment (8 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Elisa Zanardi collaborates with scholars based in Italy, United States and United Kingdom. Elisa Zanardi's co-authors include Francesco Boccardo, Carlo Cattrini, Carlo Messina, A. Rubagotti, Elena Castro, David Olmos, Filippo de Braud, Luigi Cerbone, Marco Messina and Giacomo Bregni and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Elisa Zanardi

52 papers receiving 776 citations

Peers

Countries citing papers authored by Elisa Zanardi

Since Specialization

Citations

This map shows the geographic impact of Elisa Zanardi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elisa Zanardi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elisa Zanardi more than expected).

Fields of papers citing papers by Elisa Zanardi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elisa Zanardi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elisa Zanardi. The network helps show where Elisa Zanardi may publish in the future.

Co-authorship network of co-authors of Elisa Zanardi

This figure shows the co-authorship network connecting the top 25 collaborators of Elisa Zanardi. A scholar is included among the top collaborators of Elisa Zanardi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elisa Zanardi. Elisa Zanardi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Real-life Use of Cabozantinib in Front-line therapy for Metastatic Renal Cell Carcinoma: The CabFRONT Study (Meet-URO 24) 2025 ·European Urology Open Science ·Marco Stellato, Pierangela Sepe, Enrico Bronte, Vincenza Conteduca, Maria Cossu Rocca, Ugo De Giorgi, Marilena Di Napoli, Luca Galli, Lorena Incorvaia, Luca Lalli, Brigida Anna Maiorano, Marco Maruzzo, Alessia Mennitto, Giandomenico Roviello, Matteo Santoni, Mariella Sorarů, Elisa Zanardi, Paolo Andrea Zucali, Giuseppe Procopio, Elena Verzoni	0
2	Efficacy of perioperative pembrolizumab treatment in patients with resectable metastases from kidney cancer: The PE-PE study. 2024 ·Journal of Clinical Oncology ·Roberto Iacovelli, Emanuela Fantinel, Davide Bimbatti, Sebastiano Buti, Lucia Bonomi, Mimma Rizzo, Caterina Accettura, Consuelo Buttigliero, Francesco Massari, Matteo Santoni, Paolo Andrea Zucali, Elisa Zanardi, Alessandra Mosca, (unknown), Francesco Spina, Giuseppe Procopio, Sergio Bracarda, Fabio Calabrò, Lorenzo Antonuzzo, Chiara Ciccarese	0
3	Basal cell carcinoma of the prostate: a case report of a rare prostate cancer and review of the literature. 2023 ·PubMed ·(unknown), (unknown), Pasquale Rescigno, (unknown), Elisa Zanardi, Giuseppe Fornarini, Sara Elena Rebuzzi	0
4	Cardiac Metastasis from Prostate Cancer: A Case Study Underlying the Crucial Role of the PSMA PET/CT 2023 ·Diagnostics ·(unknown), Matteo Bauckneht, (unknown), (unknown), Giuseppe Fornarini, Elisa Zanardi	2
5	The Role of mpMRI in the Assessment of Prostate Cancer Recurrence Using the PI-RR System: Diagnostic Accuracy and Interobserver Agreement in Readers with Different Expertise 2023 ·Diagnostics ·(unknown), (unknown), Michela Marcenaro, Salvina Barra, (unknown), Matteo Bauckneht, (unknown), (unknown), Carlo Terrone, Guglielmo Mantica, Marco Borghesi, Alessio Signori, Bruno Spina, (unknown), Elisa Zanardi, Giuseppe Fornarini, Jeries Paolo Zawaideh	11
6	Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for patients who are elderly (≥75 years old) with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: A SPARTACUSS–Meet-URO 26 study. 2023 ·Journal of Clinical Oncology ·(unknown), Calogero Saieva, Richard M. Lee‐Ying, Pier Vitale Nuzzo, Gian Paolo Spinelli, Elisa Zanardi, (unknown), Sabrina Rossetti, Loana Bueno Valença, Anna Patrikidou, Livia Andrade, Ricardo Pereira Mestre, Giuseppe Fornarini, Giuseppe Procopio, Daniele Santini, Christopher Sweeney, Daniel Yick Chin Heng, Ugo De Giorgi, Antonio Russo, Edoardo Francini	1
7	Opportunistic skeletal muscle metrics as prognostic tools in metastatic castration-resistant prostate cancer patients candidates to receive Radium-223 2022 ·Annals of Nuclear Medicine ·Matteo Bauckneht, (unknown), (unknown), Alberto Miceli, Maria Isabella Donegani, Cristina Campi, Daniela Schenone, Stefano Raffa, (unknown), Francesco Lanfranchi, Sara Elena Rebuzzi, Elisa Zanardi, (unknown), Cecilia Marini, Giuseppe Fornarini, Silvia Morbelli, Michele Piana, Gianmario Sambuceti	7
8	Case report: Pembrolizumab plus Axitinib related hypothyroid myopathy in two kidney cancer patients 2022 ·Frontiers in Oncology ·Andrea Boutros, Lara Vera, Federico Gatto, Giuseppe Fornarini, Elisa Zanardi	1
9	Combination therapy in metastatic renal cell carcinoma: Back to the future? 2020 ·Seminars in Oncology ·Luigi Cerbone, Carlo Cattrini, (unknown), Maria Maddalena Latocca, Francesco Boccardo, Elisa Zanardi	12
10	Insights from a Long-Term Follow-Up Evaluation of Early Breast Cancer Outcomes by Tumor Subtype 2020 ·Oncology Research and Treatment ·Elisa Zanardi, Antonio Di Meglio, (unknown), (unknown), Sandra Salvi, A. Rubagotti	2
11	BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications 2020 ·Journal of Oncology ·Carlo Messina, Carlo Cattrini, Davide Soldato, (unknown), Orazio Caffo, Elena Castro, David Olmos, Francesco Boccardo, Elisa Zanardi	78
12	Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer 2019 ·Cancers ·Carlo Cattrini, Elena Castro, (unknown), Elisa Zanardi, A. Rubagotti, Francesco Boccardo, David Olmos	53
13	Overexpression of Periostin in Tumor Biopsy Samples Is Associated With Prostate Cancer Phenotype and Clinical Outcome 2018 ·Clinical Genitourinary Cancer ·Carlo Cattrini, A. Rubagotti, Pier Vitale Nuzzo, (unknown), Sandra Salvi, Simona Boccardo, Marta Perachino, Luigi Cerbone, (unknown), Maria Maddalena Latocca, Elisa Zanardi, Francesco Boccardo	11
14	CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials 2018 ·Breast Cancer Research and Treatment ·Carlo Messina, Carlo Cattrini, Giulia Buzzatti, Luigi Cerbone, Elisa Zanardi, Marco Messina, Francesco Boccardo	51
15	Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study 2018 ·The Breast ·Matteo Lambertini, Valeria Fontana, Claudia Massarotti, Francesca Poggio, Chiara Dellepiane, (unknown), (unknown), Loredana Miglietta, (unknown), M. Pescio, Benedetta Conte, Eva Blondeaux, Claudia Bighin, Alessia D’Alonzo, (unknown), Elisa Zanardi, Francesco Boccardo, Alberto Ballestrero, Paola Anserini, Lucia Del Mastro	26
16	Targeting androgen-independent pathways: new chances for patients with prostate cancer? 2017 ·Critical Reviews in Oncology/Hematology ·Carlo Cattrini, Elisa Zanardi, (unknown), Alessia Cavo, Luigi Cerbone, Antonio Di Meglio, Chiara Fabbroni, Maria Maddalena Latocca, Fabiana Rizzo, Carlo Messina, A. Rubagotti, Paola Barboro, Francesco Boccardo	25
17	Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study 2015 ·The Oncologist ·Matteo Lambertini, Arlindo R. Ferreira, Francesca Poggio, Fabio Puglisi, Antônio Bernardo, Filippo Montemurro, Elena Poletto, (unknown), Valentina Rossi, Emanuela Risi, Antonella Lai, Elisa Zanardi, Valentina Sini, (unknown), Gabriele Minuti, Silvia Mura, Donatella Grasso, Andrea Fontana, Lucia Del Mastro	22
18	Better Together: Targeted Combination Therapies in Breast Cancer 2015 ·Seminars in Oncology ·Elisa Zanardi, Giacomo Bregni, Filippo de Braud, Serena Di Cosimo	43
19	Treatment of elderly patients with metastatic renal cell carcinoma 2015 ·Expert Review of Anticancer Therapy ·Elisa Zanardi, Paolo Grassi, Alessia Cavo, Elena Verzoni, Claudia Maggi, Filippo de Braud, Francesco Boccardo, Giuseppe Procopio	7
20	Response to trabectedin in a patient with advanced synovial sarcoma with lung metastases 2014 ·Anti-Cancer Drugs ·Elisa Zanardi, Marco Maruzzo, Maria Cristina Montesco, Anna Roma, Marco Rastrelli, Umberto Basso	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact